It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Introduction Peak incidence for many psychiatric disorders occurs in reproductive years. We don’t have FDA-approved drugs or clinical guidelines. The main cause of pharmacological suspension in pregnancy is the lack of knowledge of their effects on the product. Gathering information on this regard becomes crucial so we can avoid relapses or exacerbation Objectives Describe neurodevelopmental effects in children ≥ 6 months exposed to antipsychotics prenatally. Methods PROSPERO-CRD42020170314. Using MeSH terms in 5 databases, without language and time restriction, obtaining n=3932. After review and exclusion n=24 were obtained for qualitative review. (Figure 1). Results Of 20 case reports 4 had more ambivalence results (Table 1). In the cohort studies, exposure may cause short-term delay at 6 months but no significant difference at 12 months (Table 2). Image: Conclusions Most are case reports, hence the importance of collecting this information, not ignoring it due to lack of methodological rigor. The intent is not to conclude that prenatal exposure to antipsychotics doesn’t have long-term neurodevelopmental effects, rather documenting the available evidence contributing to an informed clinical decision. Disclosure of Interest None DeclaredStudy N Antipsychotic Months Conclusion using clinical evaluation Imaz et al. Front. Pharmacol.2018; 9:264 1 Risperdal 72 Abnormal memory, attention/executive, hyperactivity 1 Clozapine 32 Normal 2 Clozapine 18 Abnormal Normal Burt et al. Am J Psychiatry 2010; 167:892-897 1 Olanzapine 12,18, 18 months Abnormal motor 22 months normal 29 months normal Kirchheiner et al. Pharmacopsych 2000; 33:78-80 1 Olanzapine 7,11 7 months Abnormal motor Mendhekar et al. J Neuropsychiatry Clin Neurosci 2007; 19:2 1 Clozapine 6 5 years Abnormal language Study N Antipsychotic Months Conclusion using clinimetry and clinical evaluation Shao et al. Plos ONE, 2015; 10(4),1-9 63 Clozapine 6,12 BSID-III 6 months Adaptive behavior score lower in clozapine group 12 months No difference Johnson et al. Arch Gen Psychiatry2012; 69(8), 787-794 22 Haloperidol 6 INFANIB Lower scores with SGA then Haloperidol Peng et al. Psychopharmacology 2013; 228(4), 577-584 76 Clozapine 6,12 BSID-III 6 months Lower socio-emotional and adaptive behavior scores Petersen et al. BMJ 2016; 5(6), 1-9 290 FGA+SGA** 6 More neurodevelopmental disorder that those who didn’t take antipsychotics.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Psychiatry, University Hospital “Dr.José E. González” Universidad Autónoma de Nuevo León, Monterrey, Mexico